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ABSTRACT. To study the role of the redox state regulator glutathione (GSH) in bacterial lipopolysaccharide
(LPS)-induced anorexia we measured total reduced GSH (trGSH) in liver, serum and brain in response to
intraperitoneal (ip) lipopolysaccharide (LPS, 4 lg/mouse) injection in LPS-naïve and LPS-pretreated (4 lg/mouse
given 3 days earlier) mice. LPS reduced food intake in LPS-naïve mice and LPS pretreatment attenuated this
effect. LPS decreased trGSH at 24 hours after injection in LPS-naïve mice but 4 days later trGSH levels were
upregulated in brain and liver, and this was associated with a signiﬁcant attenuation of LPS-induced anorexia. In
addition, LPS increased mitochondrial GSH levels in brain and liver at 4 days after injection. Pharmacological
GSH depletion with diethylmaleate and L-buthionine sulfoximine in LPS-pretreated mice ablated the hyposen-
sitivity to the anorexic effect of LPS. Together, these ﬁndings suggest a prominent role for GSH and its
intracellular repartition in LPS anorexia.
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Inﬂammation, infection and administration of bacterial
lipopolysaccharide (LPS) cause oxidative stress, and this
entails an increase in tissue concentrations of reactive
oxygen species, which are believed to mediate tissue dys-
function and/or destruction. Consequently, antioxidants
such as glutathione (GSH) [1] are major determinants of
the degree of pathology in models of tissue inﬂammation
[2]. GSH is mainly produced in the liver and controls the
redox state in many tissues [3]. GSH has also been sup-
posed to limit LPS-induced pathology [4], but so far it is
unknown whether GSH also affects LPS anorexia. GSH
can modify cytokine production by several mechanisms
[5] and may therefore regulate anorexic cytokine produc-
tion in response to LPS. Tissue GSH may, in fact, be one
determinant of cytokine pathology. Some evidence indi-
cates that, in addition to an increase in total GSH, an
increase in mitochondrial GSH is important for its protec-
tive effect [6-9]. In this study, we investigated the role of
GSH in the food intake response to LPS in LPS-naïve and
LPS-pretreated mice. LPS pretreatment normally reduces
the pathophysiological responses and the anorexia in re-
sponse to subsequent LPS administrations, a state often
referred to as LPS tolerance [10]. If GSH modulates LPS
anorexia, its production and tissue levels in response to
LPS may differ between LPS-naïve and LPS-pretreated
animals. To examine further a possible causal relationship
between GSH and LPS anorexia, we also determined
whether pharmacological GSH depletion in LPS-
pretreated animals changes the feeding response to LPS,
and whether total or mitochondrial GSH levels in brain and
liver are indicative of tolerance to LPS-induced anorexia.
METHODS
Mice, housing and diets
We used male, 8-16 week old, 25-30g (body weight)
c57bl6 mice for all experiments. Mice were housed indi-
vidually in stainless steel cages with a grid ﬂoor and kept
on a 12:12 hour light:dark cycle. Drug solutions were
freshly prepared and always injected 1-2 hours before the
onset of the dark cycle. Mice had continuous ad libitum
access to water and powdered laboratory chow (Nafag,
Gossau, Switzerland). All procedures were approved by
the Canton of Zurich Veterinary Ofﬁce.
Experiment 1: Effects of LPS
Design (table 1) and feeding
LPS from Eschericha coli O111:B4 (L2630, Sigma,
Buchs, Switzerland) was dissolved in pyrogen-free saline
(Braun, Emmenbrucke, Switzerland) and injected intrap-
eritoneally (ip) at a dose of 4lg/mouse twice, on days 1 and
4 of the experiment, when the animals’ food intake had
returned to pre-injection values. Control animals received
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an equivalent volume of vehicle. The LPS dose chosen was
the lowest dose which caused a reliable food intake reduc-
tion for 24 hours in a preliminary experiment in WT mice
with 0, 0.4, 4 and 40 lg per 25 g body weight (n = 8/dose).
Food intake was measured (± 0.1g) at 6, 12 and 24 hours
after injection by subtracting the weight of the food con-
tainer and taking into account any spillage. At the end of
the experiment, i.e., on day 5, we collected blood, brain and
liver to determine total reduced GSH (see below). Each
treatment group shown in table 1 consisted of 7-8 mice.
Glutathione (GSH) in serum, brain and liver
For determination of trGSH, mice were sacriﬁced with CO2
24 hours after the second injection of LPS or saline. Blood
was collected by heart puncture and centrifuged. Serum was
kept at -80C° until analysis. Brains and livers were col-
lected, snap frozen in liquid nitrogen, and stored at - 80C°
until analysis. Throughout the extraction procedure for
GSH, samples were kept on ice. Tissues were homogenized
using a polytron PT1200 homogenizer (Kinematica, Luc-
ern, Switzerland) with phosphate-buffered saline (600 ll/
100 mg tissue). The solution underwent a precipitation
reaction with phosphate solution (glacial metaphosphoric
acid 1.67g, disodium EDTA 0.2 g, NaCl 30 g, in 100 ml
distilled water). This solution was centrifuged, the superna-
tant was collected, and phosphate buffer (0.3M Na2HPO4)
added. From this an aliquot was taken and the trGSH tissue
levels were measured using a method based on the forma-
tion of a chromophoric product resulting from the reaction
with 0.04% 5,5-dithiobis-2-nitrobenzoic acid (D8130,
DTNB, Sigma Chemicals, St. Louis, MO, USA) and GSH
(G4251, Sigma, Buchs, Switzerland) [11].
Mitochondrial GSH in brain and liver
In a separate group of mice, we also examined whether LPS
resulted in altered mitochondrial GSH levels in brain and
liver. On day, 5 mice (n=4, each) were perfused with ice-
cold PBS, brains and livers were removed and mitochondria
were isolated as follows [11]: tissues were homogenized in
a glass tissue grinder in a solution corresponding to 600 ll
(0.25 M sucrose – 1mM EDTA) per 100 mg of tissue. This
suspension was overlayed onto 0.34 M sucrose – 1mM
MgCl2, and 20 mM phosphate buffer (pH 7.4) and centri-
fuged at 700 g (10 min, 4°C). The resulting supernatant
was centrifuged at 5000 g for 15 min at 4°C. The pellet was
re-suspended in 40 ml of 0.25 M sucrose – 1mM EDTA
and centrifuged for 10 min at 24,000 g. The resulting pellet
was then re-suspended in 3 ml of 0.25 M sucrose and 2 mM
EDTA. Mitochondria numbers were estimated using the
succinate dehydrogenase (SDH) activity assay from the
mitochondrial preparation. Two ll were used to determine
activity by the reduction of 200 ll of succinate/nitroblue
tetrazolium solution. From the minimal activity of 0.14
optical density (OD)/min, all isolates were normalized.
GSH was then determined as described above.
Experiment 2: Effects of GSH depletion
on the responses to LPS
Design and feeding response to LPS
To determine whether GSH depletion alters the animals’
feeding response to 4lg LPS, we inhibited GSH produc-
tion and, hence, reduced GSH levels by injecting saline or
LPS-pretreated mice with diethylmaleate (DEM, D97703,
Sigma, Buchs, Switzerland) and L-buthionine sulfoximine
(BSO, B2640, Sigma, Buchs, Switzerland) (DEM/
BSO = db) at 800ll/kg body weight sc and 200 mg/kg [12]
body weight ip, 2 hours before the second LPS injection on
day 4. Preliminary trials showed that at these doses, the
combination of both inhibitors reduced trGSH in the liver
2 hours after administration. This resulted in the following
six treatment groups (n=4, each; ﬁrst injection/second
injection with or without db treatment): 1) saline/saline no
db (ss[-db]), 2) ss[+db], 3) LPS/LPS no db (ll[-db]),
4) ll[+db], 5) LPS/saline db treatment (ls[+db], and
Table 1
Time lines for treatments and food intake measurements in mice
10 11 12am 6pm 12pm 12am
DEM / BSO
injections
LPS or saline
injection
Lights out
Lights on
Food intake measurements at 6, 12 and 24 hr after LPS
LPS injection
groups
Day 1 Day 4
ss saline saline
sl saline LPS
ls LPS saline
ll LPS LPS
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6) saline/LPS db treatment (sl[+db]). Food intake was
measured at 6, 12 and 24 hours after the second LPS
injection.
Serum acute phase protein response to LPS
To determine whether GSH depletion altered the acute
phase protein response, we determined serum proteins by
cellulose gel electrophoresis (Paragon SLE gel – Beck-
man, Nyon, Switzerland). Mice groups (n = 4, each) were
deﬁned as ss[-db], ssdb[+db], ls[-db], sl[+db], ll[-db],
lldb[+db] and lsdb[-db]. Mice were sacriﬁced with CO2,
24 hours after the second injection of LPS or saline. Serum
was collected by heart puncture and stored at -80°C prior
to use. Two ll of serum were loaded on a tract and gels
were run for 30 minutes in barbital buffer. Gels were then
stained with paragon blue and scanned with the Scion
Image program. We also determined whether GSH deple-
tion by DEM/BSO altered serum proteins. Total serum
proteins levels were determined by the Bradford protein
assay (cat. No. 500-0006, Bio-Rad, Reinach, Switzerland).
Serum tumour necrosis factor- (TNF)
and interferon-c (IFNc) response to LPS
To determine whether GSH depletion in LPS-pretreated
animals altered TNFa and IFNc serum levels 24h after the
second LPS injection, we used serum from the electro-
phoresis experiment (see above) and analyzed it for TNFa
and IFNc using IFNc and TNFa murine ELISA kits from
Amersham (Otelﬁngen, Switzerland) [13].
Statistics
Differences between groups were determined by using
Kruskal-Wallis test with a Dunn post hoc test. A value of
p<0.05 was considered signiﬁcant. Non-parametrical
Spearman correlation coefﬁcients were calculated using
the Instat program (GraphPad Incorporation, San Diego,
CA, USA).
RESULTS
Experiment 1: Effects of LPS
Feeding
Administration of LPS (4 lg/mouse) on day 4 reduced
food intake compared to twice saline injected (ss) mice at
6, 12, and 24 hours in LPS naïve mice (sl) (ﬁgure 1).
LPS-pretreated mice which received a second LPS injec-
tion (ll) showed a signiﬁcant reduction in food intake at 6
and 12 hours compared to saline (ss) controls (ﬁgure 1),
but this difference did not persist over 24 hours. In addi-
tion, ll mice ate more than sl mice at 6, 12 and 24 hours
after the second injection (ﬁgure 1, n = 8, p < 0.01).
Serum, brain and liver GSH response to LPS
LPS reduced serum and brain trGSH at 24 hours after the
second injection in LPS-naïve mice (sl) compared to twice
saline-injected mice (ss) (p < 0.01). LPS-pretreated mice,
however, responded to a second LPS injection (ll) with a
signiﬁcant increase in serum and brain trGSH compared to
their saline-injected controls (p < 0.001) (ﬁgure 2). In ad-
dition, ls mice had higher trGSH levels in liver than saline
controls (ss) (p < 0.001) (ﬁgure 2).
Mitochondrial GSH in brain and liver
Four days after injection, mitochondrial GSH levels were
signiﬁcantly increased in brains and livers of LPS-treated
mice compared to their corresponding controls (ﬁgure 3).
Experiment 2: Effects of GSH depletion
on the responses to LPS
Feeding response to LPS
In Experiment 2, we conﬁrmed our previous results that
LPS injection reduced food intake compared to saline
injection in saline-pretreated control mice (sl[-db] versus
ss[-db]) at 6, 12 and 24 hours after injection (ﬁgure 4).
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Figure 1
Cumulative food intake in LPS-naïve and LPS-pretreated mice at 6, 12 and 24 hours after LPS. Mice received a ﬁrst saline (s) or LPS injection
(4lg/mouse) (l) on day 1 and a second injection of saline or LPS on day 4. This resulted in four treatment groups: saline/saline (ss), LPS/saline
(ls), saline/LPS (sl) or LPS/LPS (ll). Mice treated with only saline (ss, n = 8) and ls mice (n = 8) mice ate similar amounts of food after the second
injection. Sl mice (n = 7) showed signiﬁcant anorexia compared to ss mice at all time points (p < 0.001). LPS-pretreated mice (ll, n = 8) showed
anorexia only at 6 and 12 hours after the second LPS injection, but this was less pronounced than in sl mice at all time points. ** = p < 0.01,
*** = p < 0.001 compared to ss control mice; a = p < 0.05, b = p < 0.01, c = p < 0.001 compared to sl mice.
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time points measured (sl[-db] versus ll[-db], p < 0.01)
(ﬁgure 4, also see ﬁgure 1). GSH depletion with
DEM/BSO (db) per se (ss[+db] and ls[+db] mice) did not
affect food intake compared to saline pretreated mice
(ss[-db]) or LPS-pretreated hyposensitive mice (ll[-db]).
Yet, DEM/BSO treatment 2 hours prior to the second LPS
injection antagonized the hyposensitivity to LPS-induced
anorexia, i.e., it re-established the anorexia, in ll[+db] mice
(ﬁgure 4). Ll[+db] mice showed signiﬁcant anorexia com-
pared to their controls (ll[-db], ss[+db]) at 6 hours and 12
hours (both time points p < 0.01), but the effect did not
persist over 24 hours.
Serum acute phase protein response to LPS
GSH depletion per se resulted in no major change in serum
protein levels (ss[+db] versus ss[-db]). Similar responses
were observed in all groups, with the exception of the
ll[+db] group, in which serum protein levels were signiﬁ-
cantly increased (ﬁgure 5A). Serum electrophorograms in-
dicate that this increase in ll[+db] mice was due to a
general increase rather than an increase in a speciﬁc pro-
tein (ﬁgure 5B).
Serum TNF and IFNc response to LPS
Circulating serum IFNc levels were increased in mice that
received LPS for the ﬁrst time (sl[-db]) and in LPS-
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Figure 2
Total reduced GSH (trGSH) levels in plasma, brain and liver at 24 hours after LPS (4 lg/mouse) injection in LPS-naïve and LPS-pretreated mice.
LPS-pretreated mice (ll, n = 8) had signiﬁcantly higher plasma trGSH levels than LPS-naïve saline controls (ss, n = 8, p < 0.001). Ls mice had
signiﬁcantly higher liver trGSH levels than saline controls (ss, n = 8, p<0.001). ** = p < 0.01, *** = p < 0.001 compared to ss mice.
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Figure 3
Mitochondrial GSH repartitioning in LPS-naïve and LPS-treated mice. Mice were injected either with saline or LPS (4 lg/mouse) and were
sacriﬁced four days later to collect brain and liver. Tissues were assayed for mitochondrial GSH levels as described in Methods. LPS resulted in
increased mitochondrial GSH in both brain and liver. n = 6, * = p < 0.05, *** = p < 0.001: * or *** = comparison between LPS and saline
injected mice.
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Figure 5
Serum protein levels were similar in all treatment groups at 24h after the second injection, except for ll[+db] mice which had higher serum protein
levels than ll[-db] or ss[+db] mice (n = 4, p < 0.001) (5A). In contrast, qualitative changes due to the different treatments were revealed by the
electrophoretogram of serum protein (5B), with albumin being the least affected (large band on the left of each electrophoretogram). The location
of the gammaglobulin (c), beta-globulin (b), alpha-1-globulin (a1), alpha-2-globulin (a2) and albumin (Alb) bands are shown in 5B.
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Figure 4
Effect on LPS anorexia of GSH depletion by DEM/BSO (db) in mice. LPS-naïve or LPS-pretreated mice received either saline or db and were
then given either saline or LPS as described in Methods. After the ﬁnal injection, food intake was measured at 6, 12 and 24h. Mice receiving LPS
for the ﬁrst time sl[-db] ate less than their controls (ss[-db] or ll[-db] mice) at all time points measured (all p < 0.01). DEM/BSO attenuated the
LPS hyposensitivity, i.e., re-established the feeding inhibitory effect of LPS at 6 and 12 h in mice (ll[+db] versus ls[+db] or ss[+db] mice, p<0.01).
n=4 animals in all groups. * = p < 0.05, ** = p < 0.01 compared to ss[-db] mice; b =p < 0.01 compared to ll[-db] mice.
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second LPS injection (ll[+db]), whereas LPS-pretreated
animals without db treatment (ll[-db]) showed no increase
in either cytokine one day after the second LPS treatment
(ﬁgure 6).
DISCUSSION
Consistent with previous ﬁndings [14, 15], we report here
that ip LPS reduced food intake in LPS-naïve mice,
whereas LPS-pretreated mice showed an attenuated anor-
exia in response to the second LPS injection. Interestingly,
this phenomenon was associated with increased glu-
tathione (GSH) levels in brain and liver, raising the possi-
bility that the observed hyposensitivity to the second LPS
injection was due to high tissue GSH levels. Altering
antioxidant levels in various animal models has been
shown to change the release of cytokines in response to
immune challenges. Thus, LPS-induced cytokine produc-
tion was modiﬁed by decreasing or increasing the GSH
content with DEM/BSO [18, 19] or N-acetylcysteine [20,
21], respectively. Serum IFNc levels appeared to be sensi-
tive to GSH changes in LPS-pretreated animals as they
were increased 24 h after the second LPS treatment when
GSH was decreased. Our data suggest that LPS has a
biphasic effect on tissue GSH levels. Whereas the ﬁrst LPS
injection led to an acute decrease in serum and brain GSH,
presumably because the organism used GSH to cope with
the LPS-induced oxidative stress, four days after the ﬁrst
LPS injection, mice had increased liver GSH, perhaps as a
result of stimulated hepatic GSH production in response to
the initial demand. This additional GSH appeared to be
rapidly available when the mice were confronted with the
second LPS injection because in this situation they showed
higher serum and brain GSH levels when compared to the
twice saline-injected control mice. Thus, the stimulated
production and rapid distribution of GSH rather than el-
evated tissue levels of GSH alone may contribute to LPS
hyposensitivity. In line with this hypothesis, depletion of
GSH rendered LPS-pretreated mice susceptible to LPS
anorexia, suggesting that GSH can curb LPS-induced an-
orexia. Of course, we can also not exclude that a difference
in GSH turnover rates between LPS hypo-responsive and
LPS-naive mice contributed to the observed differences in
GSH levels because we did not measure GSH turnover.
Finally, we also demonstrate that altered intracellular GSH
repartitioning occurs in LPS hyposensitivity in both brain
and liver. Thus, we observed an increase in mitochondrial
GSH in LPS-pretreated mice compared to LPS-naïve
mice. In other oxidative stress models, increases in mito-
chondrial GSH are associated with an increased resistance
to the degree of pathology [6-9], and yet other studies have
shown that modiﬁcation of mitochondrial activity can re-
sult in resistance to LPS-induced anorexia [21-23]. Further
studies using mice with genetically altered mitochondrial
GSH levels could be used to critically examine the role of
mitochondrial GSH in LPS anorexia by using 1) increased
mitochondrial GSH transport [24] in LPS-naïve mice and
2) decreased mitochondrial GSH [25, 26] in LPS tolerance
studies. A change in the redox state can alter the immune
response due to changes in the production of cytokines
and/or acute phase proteins. It has been shown that acute
phase proteins, in particular an increase in lipoproteins
(found in the beta-globulin faction), can attenuate some of
the responses to LPS and their severity [16, 17]. Our
electrophoretograms revealed that depletion of GSH per se
did not result in a marked, qualitative decrease in the
beta-globulins. The lack of major changes between ss[-db]
and ss[+db] serum protein levels and the bands at 24 hours
after treatment suggests that the difference between ll[-db]
and ll[+db] mice was due to speciﬁc effects of GSH deple-
tion on the response to LPS. In addition, we can exclude a
general liver toxicity effect of db treatment at this time
point because albumin levels were not reduced in db
treated mice. This suggests that the reduction of GSH by
db was not due to general liver toxicity/failure. In sum-
mary, these results suggest that LPS affects GSH levels in
a tissue-speciﬁc manner and that stimulation of GSH pro-
duction and its rapid distribution in the organism rather
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Figure 6
Serum TNFa did not increase 24 hours after the second LPS injection, contrastingly, IFNc was increased in naïve mice (sl), DEM/BSO increased
IFNc in ll[+db] mice compared to ll[-db] 24 hours after the second LPS injection. n = 4 animals in all groups. *** = p < 0.001, compared to
ss[-db] mice; b = p < 0.01 compared to sl[-db] mice.
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than absolute GSH levels confer hyposensitivity to LPS
anorexia. The intracellular repartition of GSH may also be
important because hypo-responsive animals had increased
mitochondrial GSH and did not display anorexia 24 hours
after the second LPS treatment. Further support for a role
of GSH in the feeding response to LPS is derived from the
fact that mice that are hypo-responsive to the anorexic
effect of LPS because of LPS pretreatment can be rendered
sensitive again by pharmacological GSH depletion. The
generality of this phenomenon, i.e., whether for instance
IFNc-KO mice or other proinﬂammatory cytokine-
deﬁcient mice can also be made more responsive to LPS-
induced anorexia by pharmacological GSH depletion re-
mains to be examined.
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